Aptahem partners with Jarlen Capital to seek outlicensing deals

• Aptahem entered a performance-based commercial partnership with Jarlen Capital to support outlicensing efforts.
• Jarlen Capital will identify potential licensees, develop contacts, support commercial talks toward licensing, collaborations, or other transactions.
• No fixed or recurring fees; compensation only if its work results in a completed deal with an upfront payment to Aptahem.
• Payment structured as a pre-agreed success fee tied to the upfront amount received.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptahem AB published the original content used to generate this news brief via Cision (Ref. ID: 20260824:BIT:1492:0) on August 25, 2026, and is solely responsible for the information contained therein.